Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDO-1-124
- Development stage
- Preclinical
- Lead developer
- Georgetown University
- Modality
- Small Molecules
01
Overview
EDO-1-124 is a small molecule 4-aminopyrimidine derivative and symmetric analog of the compound A9. Developed by researchers at Georgetown University, it acts as a BRCA1-mimetic drug designed for the treatment of breast cancer. EDO-1-124 binds to a BRCA1-binding pocket within estrogen receptor-alpha (ERα), mimicking the tumor suppressor function of BRCA1 to inhibit ERα activity, block estrogen-stimulated gene expression, and prevent cancer cell proliferation.
- Other names
- 2,6-bis(4-methylbenzyl)-5-(4-methylphenyl)pyrimidin-4-amine4-methyl A9 analog
02
Targets
ESR1 (ERα)
Beyond the preview
Go deeper on EDO-1-124.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDO-1-124.